Kazinol B

Research use only, not for human use.

Kazinol B, a prenylated flavan with a dimethyl pyrane ring, is an inhibitor of nitric oxide (NO) production. Kazinol B improves insulin sensitivity by enhancing glucose uptake via the insulin-Akt signaling pathway and AMPK activation. Kazinol B has the potential for diabetes mellitus research.

Kazinol B is a natural isoprenylated flavan. It also stimulates the gene expression and secretion of adiponectin.

Kazinol B (2, 10 and 20 μM; 72 hours) shows no toxicity to adipocytes in 3T3-L1 cells.Kazinol B (2-20 μM; 72 hours) dose-dependently increases lipid accumulation by 2.4-fold (at 20 μM) treatment as compared with MDI-treated cells. Kazinol B (2-20 μM; 5 days) dose-dependently increases PPARγ and C/EBPα protein and mRNA levels in MDI-treated 3T3-L1 adipocytes. Kazinol B increases the mRNA level of adiponectin in a dose-dependent manner. Kazinol B (2-20 μM; 24 hours) increases the retained 2?NBDG-fluorescence in cells in a dose-dependent manner in differentiated 3T3-L1 adipocytes and C2C12 myoblasts. Kazinol B dependently increases the MDI-stimulated GLUT4 mRNA level up to 4.7-fold as compared with MDI-only treated cells. Kazinol B (10-20 μM; pre-treated for 1 h followed by 1 h insulin) dose-dependently increases insulin-dependent Akt phosphorylation. Kazinol B alone strongly induces Akt phosphorylation compared with untreated cells. Kazinol B also increased insulin-stimulated AMPK phosphorylation. Kazinol B (6.25, 12.5, 25, 50 μM; 18 hours) dose-dependently reduces amounts of iNOS protein in macrophages (RAW 264.7 cells) activated by LPS (1 ug/mL).

———

———

Others

Other Targets

———

———

———

99624-27-8

392.49

C25H28O4

>98% (HPLC)

———

C(C=C(C)C)C1=C(C=C2C(=C1O)OC(C)(C)C=C2)[C@H]3OC=4C(CC3)=CC=C(O)C4

——

(-20℃)

With Ice Pack

≥ 2 years